QuanMol co-founder and CSO Bo Li will be attending the 2024 Gordon Research Conference on Computational Chemistry, taking place in Southern Maine from July 21-26, 2024. Let’s connect and discuss how data and computation are transforming drug discovery! #grc #grc2024 #compchem #quanmol #drugdiscovery #drugdesign #biotech #pharma #quanmoltech
QuanMol Tech
生物技术研究
San Mateo，CA 484 位关注者
Let’s chat about how we’ll empower your drug discovery at [email protected]!
关于我们
At QuanMol, we are building an AI-powered precision drug design platform that routinizes the discovery of nanomolar-potency compounds. This technology platform enables multiple acceleration opportunities, including the ability to progress to ADMET and PK/PD assays much earlier. Our solutions potentially reduce the overall discovery effort by an additional 25% at only 5-10% of the traditional costs. QuanMol is a member of #EndlessFrontierLabs and #NVIDIAInception. How can we help? ?? If you are a medicinal chemist: Our platform uncovers unique structures and generates in silico SARs, significantly accelerating your projects - as proven by the success of our current collaborators! ?? If you are a biologist: Liberate yourself from chemistry challenges by working with our AI-powered medicinal chemistry experts! Our integrated discovery solutions empower you to identify high-potential development candidates with unmatched efficiency at only a fraction of traditional costs. ?? If you are a professor in related fields: Join our non-profit academic collaboration programs for projects with novel targets or MOAs. Utilize our latest AI technologies to expand the novelty and efficiency of your research. Our platform solutions are now accelerating nearly 20 discovery programs in diverse therapeutic areas, encompassing both public companies and emerging biotechs. Ready to elevate your research? Learn about how we will work with you by e-mailing [email protected] - Let's make friends!
- 网站
-
https://quanmol.com
QuanMol Tech的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Mateo，CA
- 类型
- 私人持股
地点
-
主要
获取路线
US，CA，San Mateo，94010
QuanMol Tech员工
-
Scott L Cohen
Drug Discovery Leader of Chemistry, Pre-clinical, and Clinical Development and Program Management.
-
Luis Luna
Software Engineer | Senior Business Consultant | Director of Economic Development of the City of LA Harbor and West Valley BusinessSource Center
-
Jieyu Lu
Computational Scientist @ Quanmol Tech & Ex-Meta & PhD @ NYU
-
Xingyu Shen
Founder of QuanMol Tech
动态
-
Inspiring.
I'd vote for this if I had a vote! We propose that a Nobel Prize in Physiology or Medicine should be awarded for property-based drug design, with Christopher A. Lipinski, Paul D. Leeson, and Frank Lovering as the proposed recipients for their development of “important principles for drug design”, principles that have contributed to the development of numerous approved drugs https://lnkd.in/egs6aiW7 https://lnkd.in/eg9zCCEr
-
QuanMol Tech转发了
I just registered for LSX World Congress USA, taking place on September 11-12 2024. Join me to access strategic knowledge and form new partnerships. #LSXWorld https://lnkd.in/gtmHhxft Informa Connect
LSX World Congress USA 2024
app.ingo.me
-
Scott L Cohen joins QuanMol as Partner/VP of Chemistry and Head of Drug Discovery With over 25 years in the biotech industry, Scott has led numerous therapeutic advancements from inception through to clinical development and commercialization. He has directed 18 discovery programs, advanced 6 compounds to the development-candidate stage, and brought 3 candidates into clinical stages. His contributions include developing ENTRESTO?(Sacubitril/Valsartan), an ARNi that benefits over 5 million heart failure patients annually, generating $6.5 billion in yearly revenue. He also achieved FDA breakthrough designation for Tipifarnib, a treatment for HRAS+ head and neck squamous cell carcinoma (HNSCC), and expedited the approval of Sohonos (Palovarotene) for fibrodysplasia ossificans progressiva (FOP) in various countries. His expertise spans oncology, rare diseases, cardiovascular, metabolism, and anti-infectives, yielding 57 granted patents. We look forward to working with Scott as we continue to build our drug discovery platform. Welcome onboard, Scott! #biotech #pharma #ai #drugdiscovery #drugdesign #drugdevelopment #quanmol #quanmoltech
-
QuanMol's co-founder and Chief Scientific Officer Bo Li yesterday presented how our AI-powered platform provides a technology-driven, industry-scale solution to small-molecule drug discovery. Big thanks to Q Bay Center for the invitation.
-
-
QuanMol Tech is thrilled to graduate from this year’s Endless Frontier Labs alongside an incredible cohort of innovators. We're looking forward to seeing everyone in NYC!?
Calling all #earlystage investors: Endless Frontiers Labs is hosting its annual showcase on May 9 in NYC! Meet our 55 graduating founders and learn about their cutting-edge innovations in life sciences, digital tech, and deep tech through their pitches. Connect with hundreds of investors, industry executives, scientific thought leaders, and founders in the EFL ecosystem. Preview our 23-24 Graduates and register here: https://lnkd.in/etrk2mQj
-
?? Xingyu Shen and Bo Li will attend the SDDS 2024 Stanford Drug Discovery Symposium 04/29-04/30. Interested in how QuanMol can address your medicinal chemistry challenges? Send a LinkedIn message or email us at?[email protected]?to schedule a meeting during the symposium. #sdds #stanford #biotech #pharma #ai #drugdiscovery #drugdesign #biology #quanmol #quanmoltech
-
?? One-shot design of a differentiated BRD9 inhibitor using the QuanMol ReDefine platform Bromodomain-containing protein 9 (BRD9), a promising therapeutic target in cancer treatment, has been the focus of many discovery programs, including published works by Boehringer Ingelheim, GSK, AstraZeneca, and Genentech, among others. Due to its compact protein structure, developing novel inhibitors for BRD9 with a high potency poses significant challenges. QuanMol’s one-shot de novo design of a novel BRD9 inhibitor sets a new standard of in silico discovery with: ■?60 nM Potency: Validated by SPR, this represents a significant advancement over the usual micromolar activity found in virtual screenings and is even more potent than some advanced compounds. ■?Unique Scaffold & Binding Mode: Our approach introduces a novel chemical structure with differentiated binding interactions. ■?Highly Efficient Precision Design: Created precisely in just one attempt and within two hours, demonstrating our platform's capability to significantly accelerate drug discovery. At QuanMol, we aim to narrow the translational gap in small-molecule therapeutics across the industry, enhancing your R&D efficiency with our discovery solutions. This achievement with BRD9 is a testament to our mission and the capability of the AI-powered QuanMol ReDefine platform. Interested in a partnership? Let's connect at?[email protected]. #biotech #pharma #ai #drugdiscovery #drugdesign #biology #quanmol #quanmoltech
-